Skip to main content

Table 1 Characteristics of the 33 patients

From: Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease

Variables Total (n = 33)
Age at onset of MAC, yrs ± SD 57 ± 12
Age (when found to be resistant), yrs ± SD 67 ± 9
Female, n (%) 31 (93.9)
Body mass index, kg/m2 ± SD 17.2 ± 5.0
Smoking history, n (%)  
 Current/Former/Never 0 (0)/3 (9.1)/30 (90.9)
 Pack-years ≥20, n (%) 1 (3.0)
 Alcohol abuse, n (%) 1 (3.0)
Underlying respiratory disease, n (%)  
 Old pulmonary tuberculosis 2 (6.1)
 Bronchiectasis 2 (6.1)
 Interstitial pneumonia 1 (3.0)
Underlying systematic disease, n (%)  
 Old cerebral infarction 1 (3.0)
 Diabetes mellitus 1 (3.0)
Radiographic features, n (%)  
 NB/FC 8 (24.2)/25 (75.8)
 Total lesion extenta 1/2/3, n (%) 2 (6.1)/24 (72.7)/7 (21.2)
 Cavity at the beginning of treatment, n (%) 25 (75.8)
Laboratory  
 White blood cell, /μl ± SD 5590 ± 1437
 Neutrophil, /μl ± SD 3915 ± 1291
 Hemoglobin, g/dl ± SD 12.4 ± 1.3
 Serum albumin, g/dl ± SD 3.8 ± 0.6
 CRP, mg/dl ± SD 1.9 ± 2.9
 AST, mg/dl ± SD 23 ± 7
 ALT, mg/dl ± SD 15.9 ± 8.4
 Cre, mg/dl ± SD 0.5 ± 0.14
Chronic infection with P. aeruginosa 3 (9.1)
With treatment for pulmonary aspergillosis, n (%) 4 (12.1)
Steroid use, n (%) 0 (0)
Past MAC treatment  
 CAM monotherapy, n (%) 6 (18.2)
 Two-drug regimen including CAM, n (%) 4 (12.1)
 MAC treatment more than 5 years, n (%) 20 (60.6)
  1. Data are presented as no. (%) or mean ± SD
  2. MAC Mycobacterium avium complex, NB nodular/bronchiectatic disease, FC fibrocavitary disease, CRP C-reactive protein, AST aspartate transaminase, ALT alanine transaminase, Cre creatinine, CAM clarithromycin
  3. a1, within one third of unilateral lung field; 2, within unilateral lung field; 3, over unilateral lung field